Efficacy analysis of insulin glargine combined with repaglinide in the treatment of type 2 diabetes patients with chronic renal insufficiency

Abstract

Objective To analyze the clinical efficacy and value of insulin glargine combined with repaglinide in the treatment of type 2 diabetes patients with chronic renal insufficiency. Methods 116 type 2 diabetes patients with chronic renal failure were divided into two groups according to the time of treatment.58 cases in the control group received premixed insulin treatment, while 58 cases in the observation group were given repaglinide plus insulin glargine, its clinical value was compared between the two groups. Results The FPG, 2h PG, HbAlc of the observation group were (5.90±0.62)mmol/L, (7.03±0.65)mmol/L, (6.20±0.64)%, which were significantly reduced compared with before treatment(t=8.01, 7.73, 8.82, all P<0.05), and compared with the control group, the differences were statistically significant (t=7.23, 6.83, 7.73, all P<0.05). The SCr, BUN, 24h UAE of the observation group were (90.90±8.43)μmol/L, (6.70±0.74)mmol/L, (1.20±0.34)g, which were significantly reduced than before treatment (t=7.69, 7.89, 8.02, all P<0.05), and compared with the control group, the differences were statistically significant(t=6.83, 7.03, 6.57, all P<0.05). The incidence rate of adverse reaction of the observation group was 12.07%, which was significantly lower than 34.48% of the control group(χ2=8.29, P<0.05), the main adverse reactions were hypoglycemia, patients with self-eating or oral syrup remission. Conclusion Insulin glargine combined with repaglinide in the treatment of type 2 diabetes patients with chronic renal function can control blood sugar levels, improve renal function and reduce adverse reactions, it is effective, safe, reliable and worthy of promotion. Key words: Diabetes mellitus, type 2; Renal insufficiency, chronic; Glargine; Repaglinide